Compound Primer
BPC-157 as a Research Peptide: Mechanism, Evidence, and Sourcing
Updated · 5 cited sources · ResearchChem Research Team
Short answer: BPC-157 is a research peptide: a 15-amino-acid fragment of body protection compound, a protein isolated from human gastric juice. Published work is almost entirely preclinical — cell cultures and rodent injury models — where it has been linked to fibroblast migration through the FAK-paxillin pathway, angiogenesis, and faster tendon and muscle outgrowth. Human evidence is limited to three small, low-quality studies. BPC-157 is not an approved drug and is supplied for in-vitro and animal research only.
What is BPC-157?
BPC-157 is a pentadecapeptide — a chain of 15 amino acids — corresponding to a stable fragment of body protection compound (BPC), a larger protein first isolated from human gastric juice [1]. The fragment is synthesized chemically for research use; it is not extracted from human tissue. Across the published literature it is studied as a signaling molecule for tissue-repair pathways in cell culture and in rodent injury models.
Because the material is a white lyophilized powder, the only way to confirm identity is analytical. Two vials labeled "BPC-157" from different sources can contain entirely different peptides. A mass spectrometry result, matched against the theoretical mass of the 15-residue sequence, is the standard identity check. HPLC gives the purity figure. See how to read a peptide COA for the fields a COA should carry.
ResearchChem carries BPC-157 as part of two blends only — the Wolverine Stack (TB-500 + BPC-157, 20 mg combined) and KLOW 80 (BPC-157 + TB-500 + GHK-Cu + KPV, 80 mg combined). Every lot ships with a lot number; email [email protected] for the Certificate of Analysis for your exact lot.
What mechanism has BPC-157 been linked to in research?
The clearest mechanistic data come from tendon-cell work. Using tendon fibroblasts cultured from rat Achilles tendon, Chang and colleagues reported that BPC-157 sped up fibroblast outgrowth from tendon explants, did not change proliferation in an MTT assay, improved cell survival under hydrogen-peroxide stress, and raised migration in a dose-dependent way in a transwell assay [1].
The same study found that BPC-157 increased cell spreading and F-actin formation, and that Western blots showed a dose-dependent rise in phosphorylation of focal adhesion kinase (FAK) and paxillin, with total protein levels unchanged. The authors proposed that the observed effects likely run through activation of the FAK-paxillin pathway [1].
A 2025 systematic review covering 36 studies (35 preclinical, 1 clinical) summarized the preclinical picture as follows: BPC-157 supports growth-factor signaling and angiogenesis, lowers inflammatory markers, and improves outcomes in muscle, tendon, ligament, and bone injury models in animals [2].
How strong is the evidence base?
Almost all of the published evidence for BPC-157 is preclinical: isolated cells, perfused tissue, or rodent injury models. Translating any of that to a human outcome is not a step the cited literature takes.
For human evidence, a 2026 systematic review found only three small, low-quality studies with 30 participants in total, covering knee pain, interstitial cystitis, and an intravenous safety assessment. All three reported symptom improvement in most participants and no treatment-related adverse events, but the certainty of evidence was rated very low; the authors concluded that BPC-157 should not be used clinically outside ethically approved, regulated, high-quality trials [3]. An earlier systematic review likewise found no robust human safety data and flagged risks from unregulated manufacturing and contamination [2].
What is BPC-157's regulatory status?
BPC-157 is not an approved drug anywhere. A 2026 review of approved and unapproved peptides marketed to patients lists it alongside TB-500 and thymosin beta-4 and notes that many such compounds show promising tissue-repair effects in animal studies but limited human safety data, and that patients could be seriously harmed [4]. The U.S. FDA has also placed BPC-157 arginate salt on its Category 2 list for 503A compounding — bulk substances raising significant safety risks under current review [5].
Because the compound sits in what reviewers call an unregulated gray market [4], analytical verification matters more, not less. A COA that ties a specific lot number to a mass-spec identity result and an HPLC purity figure is the practical safeguard for a research setting. See HPLC peptide purity explained for what the purity number does and does not tell you.
What should a BPC-157 COA show?
| Field | What it tells you | What to check |
|---|---|---|
| Lot number | Which production run the results belong to | Matches the lot printed on your vial |
| Sequence | Which molecule was tested | GEPPPGKPADDAGLV — the 15-residue BPC-157 sequence |
| Identity (MS) | Measured molecular mass vs theoretical mass | Observed mass close to 1,419.5 Da (monoisotopic) |
| Purity (HPLC) | Share of UV-absorbing material that is the main peak | Percentage plus the chromatogram, column, and wavelength |
| Peptide content (optional) | How much of the powder's weight is peptide vs counter-ions and water | Method stated, e.g. amino acid analysis |
| Methods and limits | How each result was produced and what counts as a pass | An acceptance criterion next to every result |
| Lab, date, sign-off | Who tested it and when | Lab name, analysis date, analyst or QA signature |
If several of these fields are missing, treat the document as marketing rather than analysis. A COA without a lot number describes some other vial.
How do researchers source BPC-157?
For a research setting, three practical checks separate a usable source from one that is not: (1) each vial carries a lot number that matches the COA's lot field; (2) the COA names a testing lab, a date, and analytical methods, not only a headline purity percentage; (3) the storage and handling instructions match what the peptide actually requires — lyophilized BPC-157 is typically stored at −20 °C and reconstituted with bacteriostatic water for in-vitro work.
ResearchChem ships BPC-157 only inside two defined blends. The Wolverine Stack pairs it with TB-500 at 20 mg combined; KLOW 80 adds GHK-Cu and KPV for 80 mg combined. Every shipped vial carries the compliance line "RESEARCH USE ONLY · NOT FOR HUMAN USE" on the 40×20 mm label. Request the Certificate of Analysis for your lot by emailing [email protected] with the lot number from the vial.
Frequently asked questions
Is BPC-157 an approved drug?
No. Reviewers describe it as an unapproved peptide sold in an unregulated gray market. The U.S. FDA has not approved it, and it cannot be used in 503A compounding under the 2023 bulk-substance determination.
What does a BPC-157 COA need to include?
A lot number that matches the vial, the sequence or molecular formula, mass-spectrometry identity, HPLC purity with the chromatogram, the testing methods and limits, and the lab and date. A COA without a matching lot describes some other vial.
How strong is the published research on BPC-157?
Almost entirely preclinical. A 2025 systematic review covered 35 preclinical studies and one clinical study. A 2026 systematic review of human evidence found three small, low-quality studies with 30 participants in total and rated the certainty of evidence as very low.
Does ResearchChem sell standalone BPC-157?
No. BPC-157 ships inside the Wolverine Stack (TB-500 + BPC-157, 20 mg) and KLOW 80 (BPC-157 + TB-500 + GHK-Cu + KPV, 80 mg). The stacks are the formats studied together in the cited preclinical tissue-repair models.
How is BPC-157 stored?
Lyophilized BPC-157 is typically stored at −20 °C in its sealed vial, and reconstituted with bacteriostatic water for in-vitro use. Storage and handling details appear on every shipped label.
Cited studies
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.. J Appl Physiol (1985). 110(3):774-80 (2011). PubMed 21030672 DOI
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.. HSS J. 21(4):485-495 (2025). PubMed 40756949 DOI
- Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety.. Acta Orthop Belg. 92(3) (2026). PubMed 42885452 DOI
- Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.. Sports Med. 56(8):1921-1935 (2026). PubMed 41966639 DOI
- U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act — Category 2 (BPC-157 arginate).. FDA.gov (2023). Source
Related compounds
- Wolverine Stack — TB-500 + BPC-157
- KLOW 80 — BPC-157 + TB-500 + GHK-Cu + KPV
Keep reading
Research use only. ResearchChem products are laboratory reagents for in-vitro research. They are not for human or veterinary consumption and are not intended to diagnose, treat, cure or prevent any disease. This article summarizes published research for educational purposes and is not medical advice.